Bayer and Salus Optima Partner on AI-Enabled Healthy Aging Journey

BayerSalus Optima, a leading provider in AI-enabled digital health and wellness solutions, and the Consumer Health division of Bayer have launched a strategic partnership to empower people on their healthy aging journey. The partnership elevates the shared aspiration of both companies to transform self-care by offering precision health solutions to enable consumers to better understand and make informed decisions about their own personal health and lifestyle choices.

With personalized, data-driven recommendations delivered through mobile applications, the partners provide consumers with tips, recommendations, and motivation to help achieve their individual lifestyle goals and empower them on their aging journey.

This collaboration will combine Salus Optima’s consumer application that provides an AI-enabled 360-degree view of the impact of lifestyle choices and related challenges that consumers face in addressing their health and wellness targets whilst leveraging Bayer’s global footprint and its broad consumer health expertise and portfolio.

Patricia Corsi, Chief Marketing & Information Officer of the Consumer Health division of Bayer commented: "There has never been a better time for our business to support consumer self-care. As the global population ages and we enter an era where many born today will live past 100 years old, understanding and taking action on aging, supported by data and science, is an exciting investment from us to our consumers. With the integration of products, platforms, and devices powered by AI, we put self-care front and center for the people we serve with our business."

Rodrigo Jesus, CEO of Salus Optima added: "We are thrilled to be working with an iconic consumer health brand such as Bayer. This allows us to accelerate time to market, expand our reach and help those that will truly benefit from precision health technologies. Our partnership will address two major global trends in consumer health: personalization and selfcare."

As part of Bayer's commitment to advance precision health and drive innovation in healthy aging, the partnership with Salus Optima follows the recent announcement of the company’s alliance with Hurdle, a pioneer in diagnostic testing. Hurdle's saliva-based biological age test will provide insights that will encourage consumers to utilize Salus Optima's digital application to define individual lifestyle goals as part of their healthy aging journey. With the launch of its precision health business unit earlier this year and these two partnerships, Bayer is building a holistic ecosystem to help address consumer needs on their healthy aging journey.

About Salus Optima

Salus Optima is a B2B, AI-enabled personalised health and wellness company affiliated with McLaren F1. It is a global leader in developing digital engagement products that provide holistic nutrition and lifestyle recommendations for healthier life, work and play. Their core technology is built on years of R&D, tackling the real problems people face in their everyday lives. Leveraging their proprietary software capability, blended with best-in-class science and data, they empower, educate and motivate people to take control over their own health and wellbeing.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2022, the Group employed around 101,000 people and had sales of 50.7 billion euros. R&D expenses before special items amounted to 6.2 billion euros.

Most Popular Now

Open Medical Works with Moray's Dig…

Open Medical is working with the Digital Health & Care Innovation Centre’s Rural Centre of Excellence on a referral management plan, as part of a research and development scheme to...

Generative AI on Track to Shape the Futu…

Using advanced artificial intelligence (AI), researchers have developed a novel method to make drug development faster and more efficient. In a new paper, Xia Ning, lead author of the study and...

AI could Help Improve Early Detection of…

A new study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center suggests that artificial intelligence (AI) could help detect interval breast cancers - those that develop between...

Reorganisation, Consolidation, and Cuts:…

NHS England has been downsized and abolished. Integrated care boards have been told to change function, consolidate, and deliver savings. Trusts are planning big cuts. The Highland Marketing advisory board...

AI-Human Task-Sharing could Cut Mammogra…

The most effective way to harness the power of artificial intelligence (AI) when screening for breast cancer may be through collaboration with human radiologists - not by wholesale replacing them...

Siemens Healthineers infection Control S…

Klinikum Region Hannover (KRH) has commissioned Siemens Healthineers to install infection control system (ICS) at the Klinikum Siloah hospital. The ICS aims to effectively tackle nosocomial infections and increase patient...

AI Tool Uses Face Photos to Estimate Bio…

Eyes may be the window to the soul, but a person's biological age could be reflected in their facial characteristics. Investigators from Mass General Brigham developed a deep learning algorithm...

Philips Future Health Index 2025 Report …

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today unveiled its 2025 Future Health Index U.S. report, "Building trust in healthcare AI," spotlighting the state of...

AI-Powered Precision: Unlocking the Futu…

A team of researchers from the Department of Diagnostic and Therapeutic Ultrasonography at the Tianjin Medical University Cancer Institute & Hospital, have published a review in Cancer Biology & Medicine...

AI Model Improves Delirium Prediction, L…

An artificial intelligence (AI) model improved outcomes in hospitalized patients by quadrupling the rate of detection and treatment of delirium. The model identifies patients at high risk for delirium and...

Building Trust in Artificial Intelligenc…

A new review, published in the peer-reviewed journal AI in Precision Oncology, explores the multifaceted reasons behind the skepticism surrounding artificial intelligence (AI) technologies in healthcare and advocates for approaches...

SALSA: A New AI Tool for the Automated a…

Investigators of the Vall d'Hebron Institute of Oncology's (VHIO) Radiomics Group, led by Raquel Perez-Lopez, have developed SALSA (System for Automatic Liver tumor Segmentation And detection), a fully automated deep...